Alliances
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial.
Specialized CRO and Leading Cancer Center to Develop New Panel of Patient-Derived Xenograft (PDX) Models from Patients with Acquired Resistance to Last-Generation Targeted Drugs in Oncology
Abu Dhabi Smart Solutions and Services Authority (ADSSSA) delivers smart government services on one digital platform to streamline and enrich customer experience
New cost competitive wafer-to-wafer layer transfer process delivers low power, increased yield and higher interconnection density and speed
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
The two companies will work on a preclinical target in hopes of finding new therapies for autoimmune diseases that regulate immune cell metabolism.
Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec’s new allosteric inhibitor platform “Targetallomod”
St. Louis, Missouri is one of the fastest-growing and top-ranked emerging life sciences markets in the U.S., ranking sixth in a recent CBRE Research report.
Hans Bishop’s Sana Biotechnology, which launched earlier this year, inked a deal with Harvard University for a foundational technology that will protect transplanted cells from immune attack.
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
PRESS RELEASES